158 related articles for article (PubMed ID: 15052821)
1. [Molecular pathogenesis of lung cancers and the preservative therapy].
Shimizu E
Nihon Naika Gakkai Zasshi; 2004 Mar; 93(3):562-8. PubMed ID: 15052821
[No Abstract] [Full Text] [Related]
2. [Progress in diagnosis and treatment of lung cancer].
Fukuoka M
Nihon Naika Gakkai Zasshi; 2002 Mar; 91 Suppl():15-22. PubMed ID: 11989256
[No Abstract] [Full Text] [Related]
3. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer.
Kandioler D; Stamatis G; Eberhardt W; Kappel S; Zöchbauer-Müller S; Kührer I; Mittlböck M; Zwrtek R; Aigner C; Bichler C; Tichy V; Hudec M; Bachleitner T; End A; Müller MR; Roth E; Klepetko W
J Thorac Cardiovasc Surg; 2008 May; 135(5):1036-41. PubMed ID: 18455581
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?
Mitsudomi T
Lancet Oncol; 2011 Aug; 12(8):710-1. PubMed ID: 21783418
[No Abstract] [Full Text] [Related]
5. Pharmacokinetics of gefitinib and erlotinib.
Levêque D
Lancet Oncol; 2011 Nov; 12(12):1093. PubMed ID: 22041538
[No Abstract] [Full Text] [Related]
6. To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress.
Costa DB
Lung Cancer; 2007 Aug; 57(2):251-2. PubMed ID: 17566601
[No Abstract] [Full Text] [Related]
7. [Latest therapeutic strategy for stage IV non-small cell lung cancer].
Kawate N
Nihon Rinsho; 2002 May; 60 Suppl 5():490-3. PubMed ID: 12101720
[No Abstract] [Full Text] [Related]
8. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
Ready N; Jänne PA; Bogart J; Dipetrillo T; Garst J; Graziano S; Gu L; Wang X; Green MR; Vokes EE;
J Thorac Oncol; 2010 Sep; 5(9):1382-90. PubMed ID: 20686428
[TBL] [Abstract][Full Text] [Related]
9. [Differences in the therapeutic strategies for lung cancer between Europe/United States and Japan].
Hanibuchi M; Yano S; Tomimoto H; Sone S
Gan To Kagaku Ryoho; 2007 May; 34(5):705-8. PubMed ID: 17496441
[TBL] [Abstract][Full Text] [Related]
10. Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?
Tsai CM; Chen JT; Stewart DJ; Chiu CH; Lai CL; Hsiao SY; Chen YM; Chang KT
J Thorac Oncol; 2011 Mar; 6(3):559-68. PubMed ID: 21258258
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
Miyauchi E; Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T;
Jpn J Clin Oncol; 2015 Jul; 45(7):670-6. PubMed ID: 25877748
[TBL] [Abstract][Full Text] [Related]
12. [Small cell lung cancer].
Yoneda S; Sakai H
Nihon Rinsho; 2002 May; 60 Suppl 5():291-3. PubMed ID: 12101675
[No Abstract] [Full Text] [Related]
13. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study.
Schuler M; Herrmann R; De Greve JL; Stewart AK; Gatzemeier U; Stewart DJ; Laufman L; Gralla R; Kuball J; Buhl R; Heussel CP; Kommoss F; Perruchoud AP; Shepherd FA; Fritz MA; Horowitz JA; Huber C; Rochlitz C
J Clin Oncol; 2001 Mar; 19(6):1750-8. PubMed ID: 11251006
[TBL] [Abstract][Full Text] [Related]
14. [New treatment strategy for stage III non-small-cell lung cancer].
Yoh K; Kubota K
Nihon Rinsho; 2002 May; 60 Suppl 5():485-9. PubMed ID: 12101719
[No Abstract] [Full Text] [Related]
15. [Non surgical new treatment modalities for lung cancer].
Kobayashi K
Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):217. PubMed ID: 11904982
[No Abstract] [Full Text] [Related]
16. Targeted therapy for lung cancer.
Kukunoor R; Shah J; Mekhail T
Curr Oncol Rep; 2003 Jul; 5(4):326-33. PubMed ID: 12781076
[TBL] [Abstract][Full Text] [Related]
17. Recent advances and future perspectives in the management of lung cancer.
Krupnick AS; Kreisel D; Hope A; Bradley J; Govindan R; Meyers B
Curr Probl Surg; 2005 Aug; 42(8):540-610. PubMed ID: 16087000
[No Abstract] [Full Text] [Related]
18. [Paclitaxel].
Hino M; Kudo S
Nihon Rinsho; 2002 May; 60 Suppl 5():343-8. PubMed ID: 12101685
[No Abstract] [Full Text] [Related]
19. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment.
Zalcman G; Schlichtholz B; Trédaniel J; Urban T; Lubin R; Dubois I; Milleron B; Hirsch A; Soussi T
Clin Cancer Res; 1998 Jun; 4(6):1359-66. PubMed ID: 9626451
[TBL] [Abstract][Full Text] [Related]
20. Patterns of practice survey for nonsmall cell lung carcinoma in the U.S.
Choy H; Shyr Y; Cmelak AJ; Mohr PJ; Johnson DH
Cancer; 2000 Mar; 88(6):1336-46. PubMed ID: 10717614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
